key: cord-0978101-jtab089h
authors: Singh, Balraj; Kaur, Parminder; Patel, Prem; Nabati, Camellia; Ayad, Sarah; Shamoon, Fayez; Maroules, Michael
title: COVID–19 and arterial thrombosis: Report of 2 cases
date: 2021-04-29
journal: Radiol Case Rep
DOI: 10.1016/j.radcr.2021.04.033
sha: 4cd14472c1fd5bb801341366b5a5b9ef0dfa6e03
doc_id: 978101
cord_uid: jtab089h

The SARS-CoV-2 infection has been predominately associated with lung disease. However, emerging evidence has associated the COVID-19 infection with a hypercoagulable state. This hypercoagulable state can occur despite the use of anticoagulants and antiplatelets. In fact, it may even be the presenting symptom of COVID–19 in some patients. Thromboembolism associated with COVID–19 carries a worse prognosis and should be identified as early as possible. Therefore, we report 2 patients with arterial thrombosis in the form of limb ischemia in the setting of COVID-19.

The first case of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) was described in Wuhan, China in December 2019 and the World Health Organization declared the disease (Coronavirus disease 2019, COVID-19) a pandemic in March 2020 [1] . Disease manifestation can vary from an asymptomatic form to severe disease-characterized by hy-✩ Competing Interests: None of the authors have any conflict of interest to disclose. * Corresponding author.

E-mail address: bsriar9@gmail.com (B. Singh).

poxemic respiratory failure, septic shock, and multiorgan dysfunction (MOD) that may require invasive mechanical ventilation and supportive treatment in critical care units [2] . It can manifest with a wide range of complications (gastrointestinal, neurological, thromboembolic and cardiovascular). It has been reported that in severe forms of COVID-19, a hypercoagulable state, characterized by micro-and macro-vascular thrombotic angiopathy occurs [3] . We report two patients with COVID-19 and arterial thrombosis. Labs were as follows: 11.9 K/mm 3 (reference: 4.5-11 K/mm 3 ), Hemoglobin: 15.3 g/dl (reference: 12-16 g/dl), platelets: 451 K/mm 3 (reference: 140-440 K/mm 3 ); sodium: 135 meq/L (reference: 135-145 meq/L); potassium 4.1 meq/L (reference: 3.5-5 meq/L), creatine 1.08 mg/dl (reference: 0.6-1.30 mg/dl), blood urea nitrogen (BUN) 29 mg/dl (reference: 7-23 mg/dl), ferritin: 760 ng/mL [16.4-294.0]; D-Dimer 2.08 mcg/mL (reference: less than 0.5); prothrombin time (PT) 13.5 seconds (reference: 12.2-14.9 seconds); international normalized ratio (INR) 1.2 (reference: less than 1), partial thromboplastin time (PTT) 26. (reference: 21.3-35.1 seconds), fibrinogen 572 (523-572); lactate dehydrogenase (LDH) 381 U/L (reference: 140-271 U/L), C-reactive protein (CRP) 22.3 mg/L (reference: less than 10 mg/L), Erythrocyte sedimentation rate (ESR) 71 mg/L (reference: less than 10 mg/L). Chest X-ray showed interstitial infiltrates throughout the right lung and to a lesser degree left base ( Fig. 1 ). Electrocardiogram (EKG) showed no evidence of acute ischemia or arrhythmias. Computed tomography (CT) scan head was unremarkable. Arterial duplex ultrasound showed extensive thrombosis of the right popliteal artery, tibioperoneal trunk, the anterior tibial, posterior tibial artery, peroneal artery and dorsalis pedis artery. Reverse transcription polymerase chain reaction (RT-PCR) nasal swab was negative; however, given clinical presentation (SOB, hypoxia), chest x-ray findings (bilateral interstitial infiltrates) and SARS-CoV-2 IgG positive there was strong suspicion for COVID-19. The patient was started on ceftriaxone, azithromycin, and therapeutic anticoagulation with heparin, ipratropium-albuterol and dexamethasone. Vascular surgery was consulted, and he underwent an angiogram ( Fig. 2 -6 ) and thrombolysis with Tissue Plasminogen Activator (tPA) and continued on therapeutic anticoagulation with heparin drip. Patient's post-operative course was uncomplicated, and he was discharged on apixaban.

A 63-year-old male with PMH of hypertension presented to the ED with complaints of fever, progressively worsening short- ness of breath, and cough for three days. He denied any known sick contacts. Of note, patient tested negative for COVID approximately 12 days prior to symptom onset. He denied chest pain, myalgias, nausea, vomiting, diarrhea or abdominal pain. In the ED, initial vital signs were significant for: temperature 36.5 °C, heart rate 115 beats per minute, respiratory rate 24-26 breaths per minute, blood pressure 140/82 mmHg, oxygen saturation 80% on room air. On physical exam, the patient was in mild respiratory distress with use of accessory muscles. Chest X-ray showed mild cardiomegaly and bilateral hazy infiltrates throughout both lung fields ( Fig. 7 ) . RT-PCR nasal swab was positive for SARS-CoV-2. Labs were as follows-WBC: 6.9 K/mm 3 , hemoglobin:13.6 g/dl, platelets: 290 k/mm 3 The patient was started on steroids, ceftriaxone, azithromycin, remdesivir and oxygen support. He received convalescent plasma also. He was also started on enoxaparin 40 subcutaneous for DVT prophylaxis. However, on day 5 of his hospitalization, he complained of acute severe left lower extremity pain. Left foot was cold to touch and a diminished dorsalis pedis pulse. Computed tomography angiogram (CT angiogram) of abdomen, aorta and iliofemoral showed an intraluminal clot in the descending thoracic aorta ( Fig. 8 ) with evidence of embolic phenomenon to the left anterior tibial, peroneal artery and distal posterior tibial ( Fig. 9 ) . The patient was started on therapeutic heparin drip and vascular surgery was consulted. His clinical condition improved with anticoagulation and without invasive intervention. He was transitioned to apixaban and was discharged on hospital day 14. 

In over a year, the Coronavirus pandemic caused by respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to many detrimental consequences and led to significant morbidity and mortality throughout the world. COVID-19 presents with a wide spectrum of clinical manifestations, from asymptomatic to a severely extensive inflammatory response that ultimately leads to pulmonary damage and end-organ failure [4] . While severe respiratory failure is the main culprit, the association between COVID-19 and coagulation dysfunction has been recently reported [4] .

While there have been ample reports of venous thromboembolism in patients with SARS-CoV-2, literature on arterial thrombosis is limited. Recent studies have shown that abnormal coagulation dysfunction is associated with poor prognosis in patients with COVID-19 [5] . In a study by Etkin et. al, the authors evaluated a total of 49 patients with arterial thromboembolism and observed a high rate of death (46%) and a high rate of limb ischemia-up to 18% of limb loss were noted in patients with COVID-19 [6] . Kashi et. al, in one article, analyzed seven patients with COVID-19 who experienced serious arterial thrombotic events despite the use of antiplatelet or anticoagulation [7] .

Goldman et al, in a retrospective study, compared patients who had CT angiogram performed-16 patients with confirmed positive SARS-CoV-2 and control 32 patients who tested negative for SARS-CoV-2. It was observed that all pa- tients (100%) who tested positive for SARS-CoV-2 had at least one thrombus while only 69% of patients who tested negative for SARS-CoV-2 had thrombi. Furthermore, they observed that death or limb amputation were more common amongst COVID-19 positive patients and thrombus burden also. Patients with COVID-19 who presented with symptoms of leg ischemia only were more likely to avoid amputation or death than patients who had pulmonary or systemic symptoms [8] .

The coagulation dysfunction is most likely secondary to the extensive inflammation from COVID-19 [3] . Furthermore, the coagulation dysfunction can be described by the Virchow's triad which consists of vascular wall injury, stasis of blood, and hypercoagulability [9] . The glycocalyx layer in the endothelium secretes tPA that prevents platelets from biding and also inhibits the activation of the clotting cascade. Invasion by the COVID-19 virus of the endothelium can lead to disruption of this process and promote formation of thrombus [9] . Additionally, abnormal blood flow and hyper viscosity can lead to both thrombosis and further endothelial injury. This is also complicated by the presence of microthrombi that is linked to COVID that further leads to turbulent blood flow [9] . Finally, the low levels of tPA associated with endothelial damage, and inhibi-tion of clot-lysing pathway, collectively promotes a hypercoagulable environment which is amplified by platelet dysfunction, and compliment activation [3] . Furthermore, extensive inflammatory response predisposed persons with COVID-19 to severe disseminated intravascular coagulation (DIC). These patients were found to have elevated levels of D-dimer, and fibrin degradation levels [3] .

SARS-CoV-2 causes severe hypoxic respiratory failure; however, there have been ample reports of many extrapulmonary manifestation including hematological complications such as severe coagulopathy. We report a case series of two patients with COVID-19 with arterial thrombosis. Our small case series adds to the available literature. Due to the fact that thrombosis can occur in spite of use of anticoagulation and antiplatelets, one needs to be cognizant of the occurrence and the associated poor prognosis related to COVID-19 coagulopathy.

None R E F E R E N C E S

Characteristics of SARS-CoV-2 and COVID-19

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72 314 cases from the chinese center for disease control and prevention

COVID-19 and its implications for thrombosis and anticoagulation

Extrapulmonary manifestations of COVID-19: radiologic and clinical overview

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Acute arterial thromboembolism in patients with COVID-19 in the new york city area

Severe arterial thrombosis associated with Covid-19 infection

Lower-extremity arterial thrombosis associated with COVID-19 is characterized by greater thrombus burden and increased rate of amputation and death

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad